PT - JOURNAL ARTICLE AU - Jianhong Zhu AU - Zhichao He AU - Dan Liang AU - Xiaoxia Yu AU - Kaifeng Qiu AU - Junyan Wu TI - Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study AID - 10.1136/thoraxjnl-2021-217575 DP - 2022 Jul 01 TA - Thorax PG - 721--723 VI - 77 IP - 7 4099 - http://thorax.bmj.com/content/77/7/721.short 4100 - http://thorax.bmj.com/content/77/7/721.full SO - Thorax2022 Jul 01; 77 AB - We examined case reports of immune checkpoint inhibitors (ICIs) associated pulmonary tuberculosis (PT) using data from the Food and Drug Administration Adverse Event Reporting System database. Disproportionality analysis was performed by using the reporting OR (ROR) with relevant 95% CI. A total of 74 cases of PT related to ICIs therapy were identified. ICIs were significantly associated with over-reporting frequencies of PT (ROR=3.16, 95% CI: 2.51 to 3.98), while the signal was differed between anti-programmed death-1/ligand-1 and anti-cytotoxic T lymphocyte antigen-4 agents. Most indications were lung cancer (64.9%), the median onset age was 70 years, the median time to onset of PT was 70 days, ICIs were discontinued in most cases (85.2%).